Literature DB >> 22439833

History of antibiotics. From salvarsan to cephalosporins.

Lorenzo Zaffiri1, Jared Gardner, Luis H Toledo-Pereyra.   

Abstract

Infections have represented for a long time the leading cause of death in humans. During the 19th century, pneumonia, tuberculosis, diarrhea and diphtheria were considered the main causes of death in children and adults. Only in the late 19th century did it become possible to correlate the existence of microscopic pathogens with the development of various diseases. Within a few years the introduction of antiseptic procedures had begun to reduce mortality due to postsurgical infections. Sanitation and hygiene played a significant role in the reduction of the mortality due to several infectious diseases. The introduction of the first compounds with antimicrobial activity succeeded in conquering many diseases. In this review we analyzed, from a historical perspective, the development of antibiotics and the circumstances that led to their discovery. The first compound with antimicrobial activity was introduced in 1911 by Erlich. He focused his research activity on the discovery of a "magic bullet" to treat syphilis. Afterwards, Foley and colleagues brought penicillin to the forefront. Streptomycin represents the first drug discovered for the treatment of tuberculosis, and its development included the first use of clinical trials. Finally, with the development of cephalosporins, the introduction of new antimicrobial compounds with broad activity against gram-positive and also some gram-negative bacteria began.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22439833     DOI: 10.3109/08941939.2012.664099

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  26 in total

1.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

2.  Specific disulfide cross-linking to constrict the mobile carrier domain of nonribosomal peptide synthetases.

Authors:  Michael J Tarry; T Martin Schmeing
Journal:  Protein Eng Des Sel       Date:  2015-02-23       Impact factor: 1.650

Review 3.  Antimicrobial peptides as natural bio-preservative to enhance the shelf-life of food.

Authors:  Mahendra Rai; Raksha Pandit; Swapnil Gaikwad; György Kövics
Journal:  J Food Sci Technol       Date:  2016-08-30       Impact factor: 2.701

4.  Current state of the art in rapid diagnostics for antimicrobial resistance.

Authors:  Rathina Kumar Shanmugakani; Balaji Srinivasan; Marshall J Glesby; Lars F Westblade; Washington B Cárdenas; Tony Raj; David Erickson; Saurabh Mehta
Journal:  Lab Chip       Date:  2020-07-09       Impact factor: 6.799

Review 5.  Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience.

Authors:  M C Flux; Christopher A Lowry
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

Review 6.  Nanomedicine to fight infectious disease.

Authors:  Kathryn M Rubey; Jacob S Brenner
Journal:  Adv Drug Deliv Rev       Date:  2021-10-08       Impact factor: 15.470

7.  Mass Spectrometry-Based Detection of Beta Lactam Hydrolysis Enables Rapid Detection of Beta Lactamase Mediated Antibiotic Resistance.

Authors:  Raymond T Suhandynata; Kyle Lund; Andrés M Caraballo-Rodríguez; Sharon L Reed; Pieter C Dorrestein; Robert L Fitzgerald; Nicholas J Bevins
Journal:  Lab Med       Date:  2022-03-07

8.  The Times they Are a-Changin' - Healthcare 4.0 Is Coming!

Authors:  Chiehfeng Chen; El-Wui Loh; Ken N Kuo; Ka-Wai Tam
Journal:  J Med Syst       Date:  2019-12-23       Impact factor: 4.460

Review 9.  Genomic and functional techniques to mine the microbiome for novel antimicrobials and antimicrobial resistance genes.

Authors:  Boahemaa Adu-Oppong; Andrew J Gasparrini; Gautam Dantas
Journal:  Ann N Y Acad Sci       Date:  2016-10-21       Impact factor: 5.691

10.  How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility.

Authors:  Magdalena Anna Massalska; Hans-Jürgen Gober
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.